文献速递关节外科

骨内注射氨甲环酸在全髋关节置换术中的疗效:前瞻性随机对照试验

Efficacy of Intraosseous Tranexamic Acid in Primary Total Hip Arthroplasty: A Prospective Randomized Controlled Trial.
PubMed 文献 · J Arthroplasty · 2026-06-22

这项等比例非劣效随机对照试验纳入126例初次全髋关节置换患者,比较骨内、静脉和局部三种途径给予氨甲环酸(TXA,20 mg/kg)的效果。主要结局为手术当日及术后第1至3天血红蛋白下降值,三组间无显著差异。骨内组在手术当日和术后第1天的计算总失血量较低,但临床意义尚不确定。

要点

  • 骨内TXA在减少血红蛋白下降方面非劣效于静脉和局部给药。
  • 骨内组手术当日及术后第1天计算总失血量较低,但临床意义待确认。
  • 三组输血率分别为2.3%、7.1%和2.3%,无显著差异。

核心结论

  • 骨内注射TXA的血液保护疗效非劣效于静脉和局部给药,可能在早期术后失血控制方面有潜在获益。

主要发现

  • 手术当日及术后第1、2、3天平均血红蛋白下降值三组间相当(P分别为0.431、0.532、0.479和0.443)。
  • 探索性分析显示骨内组手术当日和术后第1天计算总失血量低于其他组(P分别为0.005和0.016),但临床相关性尚不确定。
  • 输血率骨内组2.3%、静脉组7.1%、局部组2.3%(P=0.434)。
  • 局部组有1例发生深静脉血栓,未报告肺栓塞或感染。

关键数值与推荐

  • 骨内组TXA用法:20 mg/kg应用于股骨和髂骨松质骨。
  • 静脉组TXA用法:20 mg/kg于切皮前5分钟给药。
  • 局部组TXA用法:20 mg/kg于缝合前给药。

临床怎么用

  • 骨内TXA可作为全髋关节置换术中血液保护的替代给药途径,其疗效非劣效于静脉和局部给药。
  • 骨内给药可能在早期术后失血控制方面有潜在优势,但需进一步高质量研究确认其优越性和临床价值。

局限性

  • 骨内组早期失血量降低的临床相关性尚不确定。
  • 需要进一步高质量研究证实骨内TXA的优越性并确立其临床价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) reduces blood loss and transfusion requirements in patients who underwent primary total hip arthroplasty. However, the optimal route of TXA administration remains unclear. This randomized controlled trial evaluated whether intraosseous (IO) TXA administration was noninferior to intravenous (IV) or topical administration. METHODS: In this equal-proportion, noninferior randomized controlled trial, 126 patients undergoing primary total hip arthroplasty from October 2024 to April 2025 were randomized to IO (20 mg/kg TXA applied in the cancellous bone of the femur and ilium), IV (20 mg/kg TXA applied five minutes before incision), or topical (20 mg/kg TXA applied before suture) group. The primary outcome was hemoglobin reduction on the day of surgery (DOS) and postoperative days one to three (POD one to three). The secondary outcomes included blood loss, transfusion rate, and adverse events. Demographics were similar among the groups. RESULTS: The mean hemoglobin reduction was comparable on the DOS, POD one, POD two, and POD three (P = 0.431, 0.532, 0.479, and 0.443, respectively). Exploratory analyses showed lower mean calculated total blood loss in the IO group on the DOS and POD one than in the other groups (DOS and POD one: P = 0.005 and 0.016, respectively), although the clinical relevance of this finding remains uncertain. Transfusion rates were 2.3, 7.1, and 2.3% in the IO, IV, and topical groups, respectively (P = 0.434). There was one patient in the topical group who developed deep vein thrombosis; no pulmonary embolism or infections were reported. CONCLUSIONS: The blood-sparing efficacy of IO TXA administration is noninferior to that of IV and topical administration, with potential benefit in early postoperative blood loss control. Further high-quality studies are needed to confirm its superiority and establish its clinical value.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Chen Y, Cao L, Ji B, et al. Efficacy of Intraosseous Tranexamic Acid in Primary Total Hip Arthroplasty: A Prospective Randomized Controlled Trial. J Arthroplasty. 2026. PMID: 42331238. doi:10.1016/j.arth.2026.05.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。